Cancer drug resistance: Redox resetting renders a way

Oncotarget

Volumn 7, Issue 27, 2016, Pages 42740-42761

  Liu, Yuan ^a,b   Li, Qifu ^b   Zhou, Li ^a   Xie, Na ^a   Nice, Edouard C ^c   Zhang, Haiyuan ^b   Huang, Canhua ^a   Lei, Yunlong ^d  

^a SICHUAN UNIVERSITY   (China)

^b HAINAN MEDICAL UNIVERSITY   (China)

^c MONASH UNIVERSITY   (Australia)

^d CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Cancer therapy; Drug efflux; Drug resistance; Oxidative stress; Redox modifications

Indexed keywords

2 METHOXYESTRADIOL; ARSENIC TRIOXIDE; BORTEZOMIB; CAMPTOTHECIN; CAPECITABINE; CARBOPLATIN; CELECOXIB; CISPLATIN; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLAVOPIRIDOL; FLUOROURACIL; GEFITINIB; IMATINIB; METHOTREXATE; MITOXANTRONE; NELFINAVIR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PROCARBAZINE; SALAZOSULFAPYRIDINE; TAMOXIFEN; TANESPIMYCIN; TEMOZOLOMIDE; THAPSIGARGIN; TIOGUANINE; TUNICAMYCIN; UNINDEXED DRUG; ABC TRANSPORTER SUBFAMILY B; ABCB1 PROTEIN, HUMAN; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; ANTIOXIDANT; BREAST CANCER RESISTANCE PROTEIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; REACTIVE OXYGEN METABOLITE; TUMOR PROTEIN;

APOPTOSIS; AUTOPHAGY; CANCER RESISTANCE; CONFORMATIONAL TRANSITION; DNA REPAIR; DRUG METABOLISM; DRUG TARGETING; EPIGENETICS; GENE; GENE CONTROL; GENE EXPRESSION; HUMAN; OXIDATION REDUCTION REACTION; PROTEIN PROCESSING; REVIEW; TRANSCRIPTION REGULATION; TRANSPORTER GENE; CELL DEATH; CELL SURVIVAL; DISEASE EXACERBATION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; METABOLISM; NEOPLASM; OXIDATIVE STRESS; PATHOLOGY; PROTEIN CONFORMATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY B; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY G, MEMBER 2; AUTOPHAGY; CELL DEATH; CELL SURVIVAL; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASMS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEIN CONFORMATION; REACTIVE OXYGEN SPECIES; TREATMENT OUTCOME;

EID: 84975864025     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8600     Document Type: Review

References (198)

1. Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG. Cancer drug resistance: an evolving paradigm. Nature reviews Cancer. 2013; 13:714-726.
2. Kuczynski EA, Sargent DJ, Grothey A and Kerbel RS. Drug rechallenge and treatment beyond progression- implications for drug resistance. Nature reviews Clinical oncology. 2013; 10:571-587.
3. Bock C and Lengauer T. Managing drug resistance in cancer: lessons from HIV therapy. Nature reviews Cancer. 2012; 12:494-501.
4. Tanaka H, Matsumura I, Ezoe S, Satoh Y, Sakamaki T, Albanese C, Machii T, Pestell RG and Kanakura Y. E2F1 and c-Myc potentiate apoptosis through inhibition of NFkappaB activity that facilitates MnSOD-mediated ROS elimination. Molecular cell. 2002; 9:1017-1029.
5. Gorrini C, Harris IS and Mak TW. Modulation of oxidative stress as an anticancer strategy. Nature reviews Drug discovery. 2013; 12:931-947.
6. Nathan C and Cunningham-Bussel A. Beyond oxidative stress: an immunologist's guide to reactive oxygen species. Nature reviews Immunology. 2013; 13:349-361.
7. Trachootham D, Alexandre J and Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nature reviews Drug discovery. 2009; 8:579- 591.
8. Traverso N, Ricciarelli R, Nitti M, Marengo B, Furfaro AL, Pronzato MA, Marinari UM and Domenicotti C. Role of glutathione in cancer progression and chemoresistance. Oxidative medicine and cellular longevity. 2013; 2013:972913.
9. Tew KD, O'Brien M, Laing NM and Shen H. Coordinate changes in expression of protective genes in drug-resistant cells. Chemico-biological interactions. 1998; 111-112:199- 211.
10. Gottesman MM, Fojo T and Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature reviews Cancer. 2002; 2:48-58.
11. Borst P and Elferink RO. Mammalian ABC transporters in health and disease. Annual review of biochemistry. 2002; 71:537-592.
12. Debatin KM and Krammer PH. Death receptors in chemotherapy and cancer. Oncogene. 2004; 23:2950-2966.
13. Lowe SW, Cepero E and Evan G. Intrinsic tumour suppression. Nature. 2004; 432:307-315.
14. Wong K, Ma J, Rothnie A, Biggin PC and Kerr ID. Towards understanding promiscuity in multidrug efflux pumps. Trends in biochemical sciences. 2014; 39:8-16.
15. Higgins CF, Hiles ID, Salmond GP, Gill DR, Downie JA, Evans IJ, Holland IB, Gray L, Buckel SD, Bell AW, Hermodsend MA. A family of related ATP-binding subunits coupled to many distinct biological processes in bacteria. Nature. 1986; 323:448-450.
16. Higgins CF. Multiple molecular mechanisms for multidrug resistance transporters. Nature. 2007; 446:749-757.
17. Hohl M, Briand C, Grutter MG and Seeger MA. Crystal structure of a heterodimeric ABC transporter in its inwardfacing conformation. Nature structural & molecular biology. 2012; 19:395-402.
18. Loo TW and Clarke DM. Covalent modification of human P-glycoprotein mutants containing a single cysteine in either nucleotide-binding fold abolishes drug-stimulated ATPase activity. The Journal of biological chemistry. 1995; 270:22957-22961.
19. Jin MS, Oldham ML, Zhang Q and Chen J. Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans. Nature. 2012; 490:566-569.
20. Cole SP. Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future. Annual review of pharmacology and toxicology. 2014; 54:95-117.
21. Chen Q, Yang Y, Li L and Zhang JT. The amino terminus of the human multidrug resistance transporter ABCC1 has a U-shaped folding with a gating function. The Journal of biological chemistry. 2006; 281:31152-31163.
22. Leslie EM, Letourneau IJ, Deeley RG and Cole SP. Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1). Biochemistry. 2003; 42:5214-5224.
23. Yang Y, Chen Q and Zhang JT. Structural and functional consequences of mutating cysteine residues in the amino terminus of human multidrug resistance-associated protein The Journal of biological chemistry. 2002; 277:44268- 44277.
24. Yang Y, Liu Y, Dong Z, Xu J, Peng H, Liu Z and Zhang JT. Regulation of function by dimerization through the amino-terminal membrane-spanning domain of human ABCC1/MRP1. The Journal of biological chemistry. 2007; 282:8821-8830.
25. Yang Y, Li Z, Mo W, Ambadipudi R, Arnold RJ, Hrncirova P, Novotny MV, Georges E and Zhang JT. Human ABCC1 interacts and colocalizes with ATP synthase alpha, revealed by interactive proteomics analysis. Journal of proteome research. 2012; 11:1364-1372.
26. Maiti AK. Genetic determinants of oxidative stressmediated sensitization of drug-resistant cancer cells. International journal of cancer. 2012; 130:1-9.
27. Krause MS, Oliveira LP, Jr., Silveira EM, Vianna DR, Rossato JS, Almeida BS, Rodrigues MF, Fernandes AJ, Costa JA, Curi R and de Bittencourt PI, Jr. MRP1/GS-X pump ATPase expression: is this the explanation for the cytoprotection of the heart against oxidative stress-induced redox imbalance in comparison to skeletal muscle cells? Cell biochemistry and function. 2007; 25:23-32.
28. Mo W and Zhang JT. Human ABCG2: structure, function, and its role in multidrug resistance. International journal of biochemistry and molecular biology. 2012; 3:1-27.
29. Wakabayashi K, Tamura A, Saito H, Onishi Y and Ishikawa T. Human ABC transporter ABCG2 in xenobiotic protection and redox biology. Drug metabolism reviews. 2006; 38:371-391.
30. Mitomo H, Kato R, Ito A, Kasamatsu S, Ikegami Y, Kii I, Kudo A, Kobatake E, Sumino Y and Ishikawa T. A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. The Biochemical journal. 2003; 373:767-774.
31. Henriksen U, Fog JU, Litman T and Gether U. Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2. The Journal of biological chemistry. 2005; 280:36926-36934.
32. Kage K, Fujita T and Sugimoto Y. Role of Cys-603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2. Cancer science. 2005; 96:866-872.
33. Wakabayashi K, Nakagawa H, Adachi T, Kii I, Kobatake E, Kudo A and Ishikawa T. Identification of cysteine residues critically involved in homodimer formation and protein expression of human ATP-binding cassette transporter ABCG2: a new approach using the flp recombinase system. Journal of experimental therapeutics & oncology. 2006; 5:205-222.
34. Liu Y, Yang Y, Qi J, Peng H and Zhang JT. Effect of cysteine mutagenesis on the function and disulfide bond formation of human ABCG2. The Journal of pharmacology and experimental therapeutics. 2008; 326:33-40.
35. Thomas H and Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer control. 2003; 10:159-165.
36. Singh A, Wu H, Zhang P, Happel C, Ma J and Biswal S. Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. Molecular cancer therapeutics. 2010; 9:2365-2376.
37. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y, Yamamoto M and Talalay P. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99:11908-11913.
38. Hayes JD and McMahon M. The double-edged sword of Nrf2: subversion of redox homeostasis during the evolution of cancer. Molecular cell. 2006; 21:732-734.
39. Lau A, Villeneuve NF, Sun Z, Wong PK and Zhang DD. Dual roles of Nrf2 in cancer. Pharmacological research. 2008; 58:262-270.
40. Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, Chen W, Yi X, Zheng W, Wondrak GT, Wong PK and Zhang DD. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis. 2008; 29:1235-1243.
41. Kensler TW and Wakabayashi N. Nrf2: friend or foe for chemoprevention? Carcinogenesis. 2010; 31:90-99.
42. Ganan-Gomez I, Wei Y, Yang H, Boyano-Adanez MC and Garcia-Manero G. Oncogenic functions of the transcription factor Nrf2. Free radical biology & medicine. 2013; 65:750- 764.
43. Sporn MB and Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nature reviews Cancer. 2012; 12:564-571.
44. Kim SK, Yang JW, Kim MR, Roh SH, Kim HG, Lee KY, Jeong HG and Kang KW. Increased expression of Nrf2/ ARE-dependent anti-oxidant proteins in tamoxifen-resistant breast cancer cells. Free radical biology & medicine. 2008; 45:537-546.
45. Kaspar JW, Niture SK and Jaiswal AK. Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free radical biology & medicine. 2009; 47:1304-1309.
46. Meijerman I, Beijnen JH and Schellens JH. Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer. Cancer treatment reviews. 2008; 34:505-520.
47. Wu T, Harder BG, Wong PK, Lang JE and Zhang DD. Oxidative stress, mammospheres and Nrf2-new implication for breast cancer therapy? Molecular carcinogenesis. 2014.
48. Glasauer A and Chandel NS. Targeting antioxidants for cancer therapy. Biochemical pharmacology. 2014; 92:90- 101.
49. Myatt SS and Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nature reviews Cancer. 2007; 7:847-859.
50. Yang JY and Hung MC. A new fork for clinical application: targeting forkhead transcription factors in cancer. Clinical cancer research. 2009; 15:752-757.
51. Zhang Y, Gan B, Liu D and Paik JH. FoxO family members in cancer. Cancer biology & therapy. 2011; 12:253-259.
52. Gomes AR, Zhao F and Lam EW. Role and regulation of the forkhead transcription factors FOXO3a and FOXM1 in carcinogenesis and drug resistance. Chinese journal of cancer. 2013; 32:365-370.
53. Choi HK, Cho KB, Phuong NT, Han CY, Han HK, Hien TT, Choi HS and Kang KW. SIRT1-mediated FoxO1 deacetylation is essential for multidrug resistance-associated protein 2 expression in tamoxifen-resistant breast cancer cells. Molecular pharmaceutics. 2013; 10:2517-2527.
54. Han CY, Cho KB, Choi HS, Han HK and Kang KW. Role of FoxO1 activation in MDR1 expression in adriamycinresistant breast cancer cells. Carcinogenesis. 2008; 29:1837- 1844.
55. Putker M, Madl T, Vos HR, de Ruiter H, Visscher M, van den Berg MC, Kaplan M, Korswagen HC, Boelens R, Vermeulen M, Burgering BM and Dansen TB. Redoxdependent control of FOXO/DAF-16 by transportin-1. Molecular cell. 2013; 49:730-742.
56. Wang J, Yang H, Li W, Xu H, Yang X and Gan L. Thioredoxin 1 upregulates FOXO1 transcriptional activity in drug resistance in ovarian cancer cells. Biochimica et biophysica acta. 2015; 1852:395-405.
57. Goto T and Takano M. Transcriptional role of FOXO1 in drug resistance through antioxidant defense systems. Advances in experimental medicine and biology. 2009; 665:171-179.
58. Tezil T, Bodur C, Kutuk O and Basaga H. IKK-beta mediates chemoresistance by sequestering FOXO3; a critical factor for cell survival and death. Cellular signalling. 2012; 24:1361-1368.
59. Shiota M, Yokomizo A, Kashiwagi E, Tada Y, Inokuchi J, Tatsugami K, Kuroiwa K, Uchiumi T, Seki N and Naito S. Foxo3a expression and acetylation regulate cancer cell growth and sensitivity to cisplatin. Cancer science. 2010; 101:1177-1185.
60. Shiloh Y and Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nature reviews Molecular cell biology. 2013; 14:197-210.
61. Guo Z, Kozlov S, Lavin MF, Person MD and Paull TT. ATM activation by oxidative stress. Science. 2010; 330:517-521.
62. Guo Z, Deshpande R and Paull TT. ATM activation in the presence of oxidative stress. Cell cycle. 2010; 9:4805-4811.
63. Ke SZ, Ni XY, Zhang YH, Wang YN, Wu B and Gao FG. Camptothecin and cisplatin upregulate ABCG2 and MRP2 expression by activating the ATM/NF-kappaB pathway in lung cancer cells. International journal of oncology. 2013; 42:1289-1296.
64. Mellado W and Horwitz SB. Phosphorylation of the multidrug resistance associated glycoprotein. Biochemistry. 1987; 26:6900-6904.
65. Brennan JP, Bardswell SC, Burgoyne JR, Fuller W, Schroder E, Wait R, Begum S, Kentish JC and Eaton P. Oxidant-induced activation of type I protein kinase A is mediated by RI subunit interprotein disulfide bond formation. The Journal of biological chemistry. 2006; 281:21827-21836.
66. Giorgi C, Agnoletto C, Baldini C, Bononi A, Bonora M, Marchi S, Missiroli S, Patergnani S, Poletti F, Rimessi A, Zavan B and Pinton P. Redox control of protein kinase C: cell- and disease-specific aspects. Antioxidants & redox signaling. 2010; 13:1051-1085.
67. Blobe GC, Sachs CW, Khan WA, Fabbro D, Stabel S, Wetsel WC, Obeid LM, Fine RL and Hannun YA. Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKC alpha. The Journal of biological chemistry. 1993; 268:658-664.
68. Bates SE, Lee JS, Dickstein B, Spolyar M and Fojo AT. Differential modulation of P-glycoprotein transport by protein kinase inhibition. Biochemistry. 1993; 32:9156- 9164.
69. Vanoye CG, Castro AF, Pourcher T, Reuss L and Altenberg GA. Phosphorylation of P-glycoprotein by PKA and PKC modulates swelling-activated Cl- currents. The American journal of physiology. 1999; 276:C370-378.
70. Chen M, Xue X, Wang F, An Y, Tang D, Xu Y, Wang H, Yuan Z, Gao W, Wei J, Zhang J and Miao Y. Expression and promoter methylation analysis of ATP-binding cassette genes in pancreatic cancer. Oncology reports. 2012; 27:265- 269.
71. Baker EK and El-Osta A. MDR1, chemotherapy and chromatin remodeling. Cancer biology & therapy. 2004; 3:819-824.
72. Baker EK, Johnstone RW, Zalcberg JR and El-Osta A. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene. 2005; 24:8061-8075.
73. Elremaly W, Rouleau T and Lavoie JC. Inhibition of hepatic methionine adenosyltransferase by peroxides contaminating parenteral nutrition leads to a lower level of glutathione in newborn Guinea pigs. Free radical biology & medicine. 2012; 53:2250-2255.
74. Lertratanangkoon K, Wu CJ, Savaraj N and Thomas ML. Alterations of DNA methylation by glutathione depletion. Cancer letters. 1997; 120:149-156.
75. Alexandre J, Batteux F, Nicco C, Chereau C, Laurent A, Guillevin L, Weill B and Goldwasser F. Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. International journal of cancer. 2006; 119:41-48.
76. Llobet D, Eritja N, Encinas M, Sorolla A, Yeramian A, Schoenenberger JA, Llombart-Cussac A, Marti RM, Matias-Guiu X and Dolcet X. Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anti-cancer drugs. 2008; 19:115-124.
77. Bairati I, Meyer F, Gelinas M, Fortin A, Nabid A, Brochet F, Mercier JP, Tetu B, Harel F, Abdous B, Vigneault E, Vass S, Del Vecchio P and Roy J. Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. Journal of clinical oncology. 2005; 23:5805-5813.
78. Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ and de Vries EG. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer research. 1992; 52:6885- 6889.
79. Schwartz PM, Moir RD, Hyde CM, Turek PJ and Handschumacher RE. Role of uridine phosphorylase in the anabolism of 5-fluorouracil. Biochemical pharmacology. 1985; 34:3585-3589.
80. Houghton JA and Houghton PJ. Elucidation of pathways of 5-fluorouracil metabolism in xenografts of human colorectal adenocarcinoma. European journal of cancer & clinical oncology. 1983; 19:807-815.
81. Malet-Martino M and Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. The oncologist. 2002; 7:288-323.
82. Kosuri KV, Wu X, Wang L, Villalona-Calero MA and Otterson GA. An epigenetic mechanism for capecitabine resistance in mesothelioma. Biochemical and biophysical research communications. 2010; 391:1465-1470.
83. O'Hagan HM, Wang W, Sen S, Destefano Shields C, Lee SS, Zhang YW, Clements EG, Cai Y, Van Neste L, Easwaran H, Casero RA, Sears CL and Baylin SB. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer cell. 2011; 20:606-619.
84. Yueh MF and Tukey RH. Nrf2-Keap1 signaling pathway regulates human UGT1A1 expression in vitro and in transgenic UGT1 mice. The Journal of biological chemistry. 2007; 282:8749-8758.
85. Belanger AS, Tojcic J, Harvey M and Guillemette C. Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells. BMC molecular biology. 2010; 11:9.
86. Toffoli G, Cecchin E, Gasparini G, D'Andrea M, Azzarello G, Basso U, Mini E, Pessa S, De Mattia E, Lo Re G, Buonadonna A, Nobili S, De Paoli P and Innocenti F. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. Journal of clinical oncology. 2010; 28:866-871.
87. Klaunig JE and Kamendulis LM. The role of oxidative stress in carcinogenesis. Annual review of pharmacology and toxicology. 2004; 44:239-267.
88. Longley DB, Harkin DP and Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nature reviews Cancer. 2003; 3:330-338.
89. Field MS, Kamynina E, Watkins D, Rosenblatt DS and Stover PJ. Human mutations in methylenetetrahydrofolate dehydrogenase 1 impair nuclear de novo thymidylate biosynthesis. Proceedings of the National Academy of Sciences of the United States of America. 2015; 112:400- 405.
90. Lin X, Liu J, Maley F and Chu E. Role of cysteine amino acid residues on the RNA binding activity of human thymidylate synthase. Nucleic acids research. 2003; 31:4882-4887.
91. Chang X, Monitto CL, Demokan S, Kim MS, Chang SS, Zhong X, Califano JA and Sidransky D. Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer research. 2010; 70:2870-2879.
92. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Critical reviews in oncology/hematology. 2007; 63:12-31.
93. Plumb JA, Strathdee G, Sludden J, Kaye SB and Brown R. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer research. 2000; 60:6039- 6044.
94. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
95. Baker A, Santos BD and Powis G. Redox control of caspase-3 activity by thioredoxin and other reduced proteins. Biochemical and biophysical research communications. 2000; 268:78-81.
96. Anathy V, Roberson EC, Guala AS, Godburn KE, Budd RC and Janssen-Heininger YM. Redox-based regulation of apoptosis: S-glutathionylation as a regulatory mechanism to control cell death. Antioxidants & redox signaling. 2012; 16:496-505.
97. Pan S and Berk BC. Glutathiolation regulates tumor necrosis factor-alpha-induced caspase-3 cleavage and apoptosis: key role for glutaredoxin in the death pathway. Circulation research. 2007; 100:213-219.
98. Mitchell DA and Marletta MA. Thioredoxin catalyzes the S-nitrosation of the caspase-3 active site cysteine. Nature chemical biology. 2005; 1:154-158.
99. Mannick JB, Hausladen A, Liu L, Hess DT, Zeng M, Miao QX, Kane LS, Gow AJ and Stamler JS. Fas-induced caspase denitrosylation. Science. 1999; 284:651-654.
100. Hengartner MO. The biochemistry of apoptosis. Nature. 2000; 407:770-776.
101. Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber AO, Newell MK, Owen LB, Pope RM, Tschopp J, Wajant H, Wallach D, Wiltrout RH, Zornig M and Lynch DH. The CD95 receptor: apoptosis revisited. Cell. 2007; 129:447- 450.
102. Wang L, Azad N, Kongkaneramit L, Chen F, Lu Y, Jiang BH and Rojanasakul Y. The Fas death signaling pathway connecting reactive oxygen species generation and FLICE inhibitory protein down-regulation. Journal of immunology. 2008; 180:3072-3080.
103. Lee S, Yoon CY, Byun SS, Lee E and Lee SE. The role of c-FLIP in cisplatin resistance of human bladder cancer cells. The Journal of urology. 2013; 189:2327-2334.
104. Turkington RC, Longley DB, Allen WL, Stevenson L, McLaughlin K, Dunne PD, Blayney JK, Salto-Tellez M, Van Schaeybroeck S and Johnston PG. Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer. Cell Death Dis. 2014; 5:e1046.
105. Wilson TR, McEwan M, McLaughlin K, Le Clorennec C, Allen WL, Fennell DA, Johnston PG and Longley DB. Combined inhibition of FLIP and XIAP induces Baxindependent apoptosis in type II colorectal cancer cells. Oncogene. 2009; 28:63-72.
106. Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J and Gallick GE. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer research. 2009; 69:3842-3849.
107. Liu L, Yang M, Kang R, Wang Z, Zhao Y, Yu Y, Xie M, Yin X, Livesey KM, Loze MT, Tang D and Cao L. DAMP-mediated autophagy contributes to drug resistance. Autophagy. 2011; 7:112-114.
108. Friesen C, Fulda S and Debatin KM. Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive- and drug-resistant tumor cells. Cell death and differentiation. 1999; 6:471-480.
109. Hayes JD and Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Critical reviews in biochemistry and molecular biology. 1995; 30:445-600.
110. T Mahoney E, Byrd JC and Johnson AJ. Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Autophagy. 2013; 9:434-435.
111. Scherz-Shouval R and Elazar Z. Regulation of autophagy by ROS: physiology and pathology. Trends in biochemical sciences. 2011; 36:30-38.
112. Wu RF, Ma Z, Liu Z and Terada LS. Nox4-derived H2O2 mediates endoplasmic reticulum signaling through local Ras activation. Molecular and cellular biology. 2010; 30:3553- 3568.
113. Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L and Elazar Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. The EMBO journal. 2007; 26:1749-1760.
114. Oh SH, Kim YS, Lim SC, Hou YF, Chang IY and You HJ. Dihydrocapsaicin (DHC), a saturated structural analog of capsaicin, induces autophagy in human cancer cells in a catalase-regulated manner. Autophagy. 2008; 4:1009-1019.
115. Choi CH, Jung YK and Oh SH. Selective induction of catalase-mediated autophagy by dihydrocapsaicin in lung cell lines. Free radical biology & medicine. 2010; 49:245- 257.
116. Kim Y and Sun H. Functional genomic approach to identify novel genes involved in the regulation of oxidative stress resistance and animal lifespan. Aging cell. 2007; 6:489-503.
117. Bouwman P and Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nature reviews Cancer. 2012; 12:587-598.
118. Dally H and Hartwig A. Induction and repair inhibition of oxidative DNA damage by nickel(II) and cadmium(II) in mammalian cells. Carcinogenesis. 1997; 18:1021-1026.
119. Bravard A, Vacher M, Gouget B, Coutant A, de Boisferon FH, Marsin S, Chevillard S and Radicella JP. Redox regulation of human OGG1 activity in response to cellular oxidative stress. Molecular and cellular biology. 2006; 26:7430-7436.
120. Noren Hooten N, Kompaniez K, Barnes J, Lohani A and Evans MK. Poly(ADP-ribose) polymerase 1 (PARP-1) binds to 8-oxoguanine-DNA glycosylase (OGG1). The Journal of biological chemistry. 2011; 286:44679-44690.
121. Das S, Chattopadhyay R, Bhakat KK, Boldogh I, Kohno K, Prasad R, Wilson SH and Hazra TK. Stimulation of NEIL2- mediated oxidized base excision repair via YB-1 interaction during oxidative stress. The Journal of biological chemistry. 2007; 282:28474-28484.
122. Cuneo MJ and London RE. Oxidation state of the XRCC1 N-terminal domain regulates DNA polymerase beta binding affinity. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107:6805-6810.
123. Kelley MR, Georgiadis MM and Fishel ML. APE1/Ref-role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1. Current molecular pharmacology. 2012; 5:36-53.
124. Luo M, Delaplane S, Jiang A, Reed A, He Y, Fishel M, Nyland RL, 2nd, Borch RF, Qiao X, Georgiadis MM and Kelley MR. Role of the multifunctional DNA repair and redox signaling protein Ape1/Ref-1 in cancer and endothelial cells: small-molecule inhibition of the redox function of Ape1. Antioxidants & redox signaling. 2008; 10:1853-1867.
125. Evans AR, Limp-Foster M and Kelley MR. Going APE over ref-1. Mutation research. 2000; 461:83-108.
126. Naidu MD, Mason JM, Pica RV, Fung H and Pena LA. Radiation resistance in glioma cells determined by DNA damage repair activity of Ape1/Ref-1. Journal of radiation research. 2010; 51:393-404.
127. Silber JR, Bobola MS, Blank A, Schoeler KD, Haroldson PD, Huynh MB and Kolstoe DD. The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress. Clinical cancer research. 2002; 8:3008- 3018.
128. Bobola MS, Jankowski PP, Gross ME, Schwartz J, Finn LS, Blank A, Ellenbogen RG and Silber JR. Apurinic/ apyrimidinic endonuclease is inversely associated with response to radiotherapy in pediatric ependymoma. International journal of cancer. 2011; 129:2370-2379.
129. Chen S, Xiong G, Wu S and Mo J. Downregulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 enhances the sensitivity of human pancreatic cancer cells to radiotherapy in vitro. Cancer biotherapy & radiopharmaceuticals. 2013; 28:169-176.
130. Ramana CV, Boldogh I, Izumi T and Mitra S. Activation of apurinic/apyrimidinic endonuclease in human cells by reactive oxygen species and its correlation with their adaptive response to genotoxicity of free radicals. Proceedings of the National Academy of Sciences of the United States of America. 1998; 95:5061-5066.
131. Pines A, Perrone L, Bivi N, Romanello M, Damante G, Gulisano M, Kelley MR, Quadrifoglio F and Tell G. Activation of APE1/Ref-1 is dependent on reactive oxygen species generated after purinergic receptor stimulation by ATP. Nucleic acids research. 2005; 33:4379-4394.
132. Hsieh MM, Hegde V, Kelley MR and Deutsch WA. Activation of APE/Ref-1 redox activity is mediated by reactive oxygen species and PKC phosphorylation. Nucleic acids research. 2001; 29:3116-3122.
133. Bennett SM, Neher TM, Shatilla A and Turchi JJ. Molecular analysis of Ku redox regulation. BMC molecular biology. 2009; 10:86.
134. Falck J, Coates J and Jackson SP. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature. 2005; 434:605-611.
135. Andrews BJ, Lehman JA and Turchi JJ. Kinetic analysis of the Ku-DNA binding activity reveals a redox-dependent alteration in protein structure that stimulates dissociation of the Ku-DNA complex. The Journal of biological chemistry. 2006; 281:13596-13603.
136. Ayene IS, Stamato TD, Mauldin SK, Biaglow JE, Tuttle SW, Jenkins SF and Koch CJ. Mutation in the glucose-6- phosphate dehydrogenase gene leads to inactivation of Ku DNA end binding during oxidative stress. The Journal of biological chemistry. 2002; 277:9929-9935.
137. Cosentino C, Grieco D and Costanzo V. ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair. The EMBO journal. 2011; 30:546-555.
138. Men L, Roginskaya M, Zou Y and Wang Y. Redoxdependent formation of disulfide bonds in human replication protein A. Rapid communications in mass spectrometry: RCM. 2007; 21:2743-2749.
139. Penney RB and Roy D. Thioredoxin-mediated redox regulation of resistance to endocrine therapy in breast cancer. Biochimica et biophysica acta. 2013; 1836:60-79.
140. Silber JR, Blank A, Bobola MS, Ghatan S, Kolstoe DD and Berger MS. O6-methylguanine-DNA methyltransferasedeficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clinical cancer research. 1999; 5:807-814.
141. Fu D, Calvo JA and Samson LD. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nature reviews Cancer. 2012; 12:104-120.
142. Haar CP, Hebbar P, Wallace GCt, Das A, Vandergrift WA, 3rd, Smith JA, Giglio P, Patel SJ, Ray SK and Banik NL. Drug resistance in glioblastoma: a mini review. Neurochemical research. 2012; 37:1192-1200.
143. Liu L and Gerson SL. Targeted modulation of MGMT: clinical implications. Clinical cancer research. 2006; 12:328-331.
144. Brown R, Curry E, Magnani L, Wilhelm-Benartzi CS and Borley J. Poised epigenetic states and acquired drug resistance in cancer. Nature reviews Cancer. 2014; 14:747- 753.
145. Ahuja N, Easwaran H and Baylin SB. Harnessing the potential of epigenetic therapy to target solid tumors. The Journal of clinical investigation. 2014; 124:56-63.
146. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC and Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New England journal of medicine. 2005; 352:997-1003.
147. Reliene R and Schiestl RH. Antioxidant N-acetyl cysteine reduces incidence and multiplicity of lymphoma in Atm deficient mice. DNA repair. 2006; 5:852-859.
148. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE and Chumakov PM. The antioxidant function of the p53 tumor suppressor. Nature medicine. 2005; 11:1306-1313.
149. Gao P, Zhang H, Dinavahi R, Li F, Xiang Y, Raman V, Bhujwalla ZM, Felsher DW, Cheng L, Pevsner J, Lee LA, Semenza GL and Dang CV. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer cell. 2007; 12:230- 238.
150. Klein EA, Thompson IM, Jr., Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Jama. 2011; 306:1549-1556.
151. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S and Hammar S. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. The New England journal of medicine. 1996; 334:1150-1155.
152. Piskounova E, Agathocleous M, Murphy MM, Hu Z, Huddlestun SE, Zhao Z, Leitch AM, Johnson TM, DeBerardinis RJ and Morrison SJ. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature. 2015; 527:186-191.
153. Le Gal K, Ibrahim MX, Wiel C, Sayin VI, Akula MK, Karlsson C, Dalin MG, Akyurek LM, Lindahl P, Nilsson J and Bergo MO. Antioxidants can increase melanoma metastasis in mice. Science translational medicine. 2015; 7:308re308.
154. Lenehan PF, Gutierrez PL, Wagner JL, Milak N, Fisher GR and Ross DD. Resistance to oxidants associated with elevated catalase activity in HL-60 leukemia cells that overexpress multidrug-resistance protein does not contribute to the resistance to daunorubicin manifested by these cells. Cancer chemotherapy and pharmacology. 1995; 35:377-386.
155. Zhou P, Kalakonda N and Comenzo RL. Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. British journal of haematology. 2005; 128:636-644.
156. Ramanathan B, Jan KY, Chen CH, Hour TC, Yu HJ and Pu YS. Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer research. 2005; 65:8455-8460.
157. Hoshida Y, Moriyama M, Otsuka M, Kato N, Taniguchi H, Shiratori Y, Seki N and Omata M. Gene expressions associated with chemosensitivity in human hepatoma cells. Hepato-gastroenterology. 2007; 54:489-492.
158. Zhou Y, Hileman EO, Plunkett W, Keating MJ and Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood. 2003; 101:4098-4104.
159. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, Eckman J, Goodman M, Fernandez HF, Boise LH and Lee KP. Feasibility and correlates of arsenic trioxide combined with ascorbic acidmediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clinical cancer research. 2002; 8:3658-3668.
160. Yoshida T, Goto S, Kawakatsu M, Urata Y and Li TS. Mitochondrial dysfunction, a probable cause of persistent oxidative stress after exposure to ionizing radiation. Free radical research. 2012; 46:147-153.
161. Chen P, Wang H, Duan Z, Zou JX, Chen H, He W and Wang J. Estrogen-related receptor alpha confers methotrexate resistance via attenuation of reactive oxygen species production and P53 mediated apoptosis in osteosarcoma cells. BioMed research international. 2014; 2014:616025.
162. Arnold M, Bissinger R and Lang F. Mitoxantrone-induced suicidal erythrocyte death. Cellular physiology and biochemistry. 2014; 34:1756-1767.
163. Lee YH, Kang BS and Bae YS. Premature senescence in human breast cancer and colon cancer cells by tamoxifenmediated reactive oxygen species generation. Life sciences. 2014; 97:116-122.
164. Marullo R, Werner E, Degtyareva N, Moore B, Altavilla G, Ramalingam SS and Doetsch PW. Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PloS one. 2013; 8:e81162.
165. Liu W, Gu J, Qi J, Zeng XN, Ji J, Chen ZZ and Sun XL. Lentinan exerts synergistic apoptotic effects with paclitaxel in A549 cells via activating ROS-TXNIP-NLRP3 inflammasome. Journal of cellular and molecular medicine. 2015; 19:1949-55.
166. Fan C, Zheng W, Fu X, Li X, Wong YS and Chen T. Strategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling. Oncotarget. 2014; 5:2853-2863. doi: 10.18632/ oncotarget.1854.
167. Tibullo D, Barbagallo I, Giallongo C, La Cava P, Parrinello N, Vanella L, Stagno F, Palumbo GA, Li Volti G and Di Raimondo F. Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells. Current pharmaceutical design. 2013; 19:2765-2770.
168. Jayasooriya RG, Choi YH, Hyun JW and Kim GY. Camptothecin sensitizes human hepatoma Hep3B cells to TRAIL-mediated apoptosis via ROS-dependent death receptor 5 upregulation with the involvement of MAPKs. Environmental toxicology and pharmacology. 2014; 38:959-967.
169. Ge Y, Byun JS, De Luca P, Gueron G, Yabe IM, Sadiq-Ali SG, Figg WD, Quintero J, Haggerty CM, Li QQ, De Siervi A and Gardner K. Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro-phenyl)-4,5,6,7- tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and flavopiridol. Molecular pharmacology. 2008; 74:872-883.
170. Gueranger Q, Li F, Peacock M, Larnicol-Fery A, Brem R, Macpherson P, Egly JM and Karran P. Protein oxidation and DNA repair inhibition by 6-thioguanine and UVA radiation. The Journal of investigative dermatology. 2014; 134:1408-1417.
171. Wang J and Yi J. Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer biology & therapy. 2008; 7:1875-1884.
172. Montero AJ, Diaz-Montero CM, Deutsch YE, Hurley J, Koniaris LG, Rumboldt T, Yasir S, Jorda M, Garret-Mayer E, Avisar E, Slingerland J, Silva O, Welsh C, Schuhwerk K, Seo P, Pegram MD, et al. Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. Breast cancer research and treatment. 2012; 132:215-223.
173. Lo M, Ling V, Low C, Wang YZ and Gout PW. Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer. Current oncology. 2010; 17:9-16.
174. Guan J, Lo M, Dockery P, Mahon S, Karp CM, Buckley AR, Lam S, Gout PW and Wang YZ. The xc- cystine/ glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine. Cancer chemotherapy and pharmacology. 2009; 64:463-472.
175. Dufour E, Gay F, Aguera K, Scoazec JY, Horand F, Lorenzi PL and Godfrin Y. Pancreatic tumor sensitivity to plasma L-asparagine starvation. Pancreas. 2012; 41:940-948.
176. Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, Goekbuget N, Schrappe M and Pui CH. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011; 117:238- 249.
177. O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL and Ozols RF. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. Journal of clinical oncology. 1996; 14:249-256.
178. Lewis-Wambi JS, Kim HR, Wambi C, Patel R, Pyle JR, Klein-Szanto AJ and Jordan VC. Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis. Breast cancer research: BCR. 2008; 10:R104.
179. Brozovic A, Vukovic L, Polancac DS, Arany I, Koberle B, Fritz G, Fiket Z, Majhen D, Ambriovic-Ristov A and Osmak M. Endoplasmic reticulum stress is involved in the response of human laryngeal carcinoma cells to Carboplatin but is absent in Carboplatin-resistant cells. PloS one. 2013; 8:e76397.
180. Yamaguchi H, Hsu JL, Chen CT, Wang YN, Hsu MC, Chang SS, Du Y, Ko HW, Herbst R and Hung MC. Caspase-independent cell death is involved in the negative effect of EGF receptor inhibitors on cisplatin in non-small cell lung cancer cells. Clinical cancer research. 2013; 19:845-854.
181. Halliwell B. Oxidative stress and cancer: have we moved forward? The Biochemical journal. 2007; 401:1-11.
182. Takeda S, Nishimura H, Koyachi K, Matsumoto K, Yoshida K, Okamoto Y, Amamoto T, Shindo M and Aramaki H. (-)-Xanthatin induces the prolonged expression of c-Fos through an N-acetyl-L-cysteine (NAC)-sensitive mechanism in human breast cancer MDA-MB-231 cells. The Journal of toxicological sciences. 2013; 38:547-557.
183. Zhang Y, Soboloff J, Zhu Z and Berger SA. Inhibition of Ca2+ influx is required for mitochondrial reactive oxygen species-induced endoplasmic reticulum Ca2+ depletion and cell death in leukemia cells. Molecular pharmacology. 2006; 70:1424-1434.
184. Demidem A, Morvan D and Madelmont JC. Bystander effects are induced by CENU treatment and associated with altered protein secretory activity of treated tumor cells: a relay for chemotherapy? International journal of cancer. 2006; 119:992-1004.
185. Lin CJ, Lee CC, Shih YL, Lin CH, Wang SH, Chen TH and Shih CM. Inhibition of mitochondria- and endoplasmic reticulum stress-mediated autophagy augments temozolomide-induced apoptosis in glioma cells. PloS one. 2012; 7:e38706.
186. Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE and Chen CS. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosisinducing agents. Journal of the National Cancer Institute. 2002; 94:1745-1757.
187. Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, Hollander MC, Kawabata S, Tsokos M, Figg WD, Steeg PS and Dennis PA. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clinical cancer research. 2007; 13:5183-5194.
188. Chen Z, Pittman EF, Romaguera J, Fayad L, Wang M, Neelapu SS, McLaughlin P, Kwak L and McCarty N. Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma. PloS one. 2013; 8:e69126.
189. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R and Pazdur R. Bortezomib for the treatment of mantle cell lymphoma. Clinical cancer research. 2007; 13:5291-5294.
190. Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R and Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacological reports: PR. 2009; 61:154-171.
191. Neckers L and Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clinical cancer research. 2012; 18:64-76.
192. Lee RA, Kim HA, Kang BY and Kim KH. Hemoglobin induces colon cancer cell proliferation by release of reactive oxygen species. World journal of gastroenterology. 2006; 12:5644-5650.
193. Miller WH, Jr., Schipper HM, Lee JS, Singer J and Waxman S. Mechanisms of action of arsenic trioxide. Cancer research. 2002; 62:3893-3903.
194. Zhang Q, Ma Y, Cheng YF, Li WJ, Zhang Z and Chen SY. Involvement of reactive oxygen species in 2-methoxyestradiol-induced apoptosis in human neuroblastoma cells. Cancer letters. 2011; 313:201-210.
195. Lai WL and Wong NS. ROS mediates 4HPR-induced posttranscriptional expression of the Gadd153 gene. Free radical biology & medicine. 2005; 38:1585-1593.
196. Luo X and Kraus WL. On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes & development. 2012; 26:417-432.
197. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B, 3rd and Stockwell BR. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012; 149:1060-1072.
198. Yagoda N, von Rechenberg M, Zaganjor E, Bauer AJ, Yang WS, Fridman DJ, Wolpaw AJ, Smukste I, Peltier JM, Boniface JJ, Smith R, Lessnick SL, Sahasrabudhe S and Stockwell BR. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature. 2007; 447:864-868.